Jie Chen, Suna Fu, Jianhong Yu, Qi Tang, Xiuping Wu, Sai Luo, Huifang Sun
{"title":"改良格拉斯哥预后评分作为预测膀胱癌和前列腺癌患者预后的标志物：一项系统回顾和荟萃分析。","authors":"Jie Chen, Suna Fu, Jianhong Yu, Qi Tang, Xiuping Wu, Sai Luo, Huifang Sun","doi":"10.1159/000545001","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to investigate the association of pre-treatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC).</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS, and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random-effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7).</p><p><strong>Results: </strong>Of 20 studies included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR: 2.65; 95% CI: 1.99, 3.52), CSS (HR: 1.64; 95% CI: 1.19, 2.26), and RFS (HR: 1.77; 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger's p > 0.05). These associations remained valid in subgroup analysis.</p><p><strong>Conclusion: </strong>Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-14"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modified Glasgow Prognostic Score as a Marker for Predicting Outcomes in Patients with either Bladder or Prostate Cancer: A Systematic Review and Meta-Analysis.\",\"authors\":\"Jie Chen, Suna Fu, Jianhong Yu, Qi Tang, Xiuping Wu, Sai Luo, Huifang Sun\",\"doi\":\"10.1159/000545001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The aim of this study was to investigate the association of pre-treatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC).</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS, and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random-effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7).</p><p><strong>Results: </strong>Of 20 studies included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR: 2.65; 95% CI: 1.99, 3.52), CSS (HR: 1.64; 95% CI: 1.19, 2.26), and RFS (HR: 1.77; 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger's p > 0.05). These associations remained valid in subgroup analysis.</p><p><strong>Conclusion: </strong>Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":\" \",\"pages\":\"1-14\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000545001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Modified Glasgow Prognostic Score as a Marker for Predicting Outcomes in Patients with either Bladder or Prostate Cancer: A Systematic Review and Meta-Analysis.
Introduction: The aim of this study was to investigate the association of pre-treatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC).
Methods: A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS, and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random-effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7).
Results: Of 20 studies included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR: 2.65; 95% CI: 1.99, 3.52), CSS (HR: 1.64; 95% CI: 1.19, 2.26), and RFS (HR: 1.77; 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger's p > 0.05). These associations remained valid in subgroup analysis.
Conclusion: Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
